Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Kite Pharma

    - PMLiVE

    Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

    This is the most common type of non-Hodgkin lymphoma worldwide

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

    The rare liver disease affects approximately 15 per 100,000 people in Europe

    - PMLiVE

    Gilead’s Livdelzi receives FDA accelerated approval to treat primary biliary cholangitis

    The company gained access to the drug through its $4.3bn acquisition of CymaBay in March

    - PMLiVE

    Kite and Arcellx expand cell therapy partnership in deal worth over $285m

    The companies' existing CART-ddBCMA collaboration now covers lymphomas

    - PMLiVE

    Kite’s CAR-T therapies recommended by NICE for certain blood cancers

    The two treatments could benefit up to 600 patients each year in England

    - PMLiVE

    Gilead’s Trodelvy shows promise in phase 2 bladder cancer study

    An estimated 83,000 Americans will be diagnosed with bladder cancer in 2023

    - PMLiVE

    Gilead’s Trodelvy approved by FDA for metastatic breast cancer

    HR+/HER2- is the most common type of breast cancer, accounting for 70% of new cases

    - PMLiVE

    Gilead’s CAR-T cell therapy recommended by NICE for lymphoma

    Yescarta is the first CAR T-cell therapy recommended for routine use on the NHS

    - PMLiVE

    Gilead and EVOQ Therapeutics partner in deal potentially worth over $650m

    The companies will focus on developing therapies for rheumatoid arthritis and lupus

    - PMLiVE

    Kite announces acquisition of Tmunity Therapeutics in latest agreement

    The acquisition will include Tmunity’s ‘armoured’ CAR T technology platform

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links